Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called ‘Act4Biosimilars’ to help address health inequity and inequality worldwide. Act4Biosimilars aims to increase patient access to advanced medicines by facilitating greater approvability, accessibility, acceptability and affordability (the 4 A’s) of biosimilars.
Sandoz announces new global ‘Act4Biosimilars’ initiative
June 3, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022